Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Silvia Valbuena LópezESC GUIDELINES ON DIABETES
European Heart Journal, ehz467, https://doi.org/10.1093/eurheartj/ehz467
Silvia Valbuena LópezESC GUIDELINES ON DIABETES
What´s new in the 2019 Guidelines?
 Reclassification of CV risk in diabet...
Silvia Valbuena LópezESC GUIDELINES ON DIABETES
CV risk categories in patients with DM
Silvia Valbuena LópezESC GUIDELINES ON DIABETES
Imaging techniques as risk modifiers
Silvia Valbuena LópezESC GUIDELINES ON DIABETES
CV outcome trials with newer glucose lowering agents
16 CV outcome trials ...
Silvia Valbuena LópezESC GUIDELINES ON DIABETES
Recommendations for glucose-lowering treatment
Silvia Valbuena LópezESC GUIDELINES ON DIABETES
New treatment algorhythm for treatment of DM
Silvia Valbuena LópezESC GUIDELINES ON DIABETES
LIPID TARGET AND MANAGEMENT
Silvia Valbuena LópezESC GUIDELINES ON DIABETES
BLOOD PRESSURE TARGET AND MANAGEMENT
Silvia Valbuena LópezESC GUIDELINES ON DIABETES
ANTITHROMBOTIC THERAPY
Primary prevention
DAPT Oral anticoagulation
Silvia Valbuena LópezESC GUIDELINES ON DIABETES
MYOCARDIAL REVASCULARIZATION
Silvia Valbuena LópezESC GUIDELINES ON DIABETES
LIFESTYLE INTERVENTION AND MULTIFACTORIAL MANAGEMENT
Silvia Valbuena LópezESC GUIDELINES ON DIABETES
• Cambio de paradigma en el uso de fármacos hipoglucemiantes 
peso de la ...
Upcoming SlideShare
Loading in …5
×

5. ESC Guidelines on Diabetes

170 views

Published on

La Dra. Silvia Valbuena López resalta los aspectos más relevantes de las nuevas guías europeas de diabetes, publicadas en París.

Published in: Health & Medicine
  • Be the first to comment

5. ESC Guidelines on Diabetes

  1. 1. Silvia Valbuena LópezESC GUIDELINES ON DIABETES European Heart Journal, ehz467, https://doi.org/10.1093/eurheartj/ehz467
  2. 2. Silvia Valbuena LópezESC GUIDELINES ON DIABETES What´s new in the 2019 Guidelines?  Reclassification of CV risk in diabetes  New treatment algorhythms with glucose-lowering agents for managenment/prevention of CVD  New lipid targets relating to severity of CV risk / new recommendations for the use of PCSK9 inhibitors  Individualised blood pressure targets  New recommendations regarding the role of aspirin and NOACs / duration of DAPT post-ACS in diabetes  Choice of revascularization techniques
  3. 3. Silvia Valbuena LópezESC GUIDELINES ON DIABETES CV risk categories in patients with DM
  4. 4. Silvia Valbuena LópezESC GUIDELINES ON DIABETES Imaging techniques as risk modifiers
  5. 5. Silvia Valbuena LópezESC GUIDELINES ON DIABETES CV outcome trials with newer glucose lowering agents 16 CV outcome trials between 2013 and 2019
  6. 6. Silvia Valbuena LópezESC GUIDELINES ON DIABETES Recommendations for glucose-lowering treatment
  7. 7. Silvia Valbuena LópezESC GUIDELINES ON DIABETES New treatment algorhythm for treatment of DM
  8. 8. Silvia Valbuena LópezESC GUIDELINES ON DIABETES LIPID TARGET AND MANAGEMENT
  9. 9. Silvia Valbuena LópezESC GUIDELINES ON DIABETES BLOOD PRESSURE TARGET AND MANAGEMENT
  10. 10. Silvia Valbuena LópezESC GUIDELINES ON DIABETES ANTITHROMBOTIC THERAPY Primary prevention DAPT Oral anticoagulation
  11. 11. Silvia Valbuena LópezESC GUIDELINES ON DIABETES MYOCARDIAL REVASCULARIZATION
  12. 12. Silvia Valbuena LópezESC GUIDELINES ON DIABETES LIFESTYLE INTERVENTION AND MULTIFACTORIAL MANAGEMENT
  13. 13. Silvia Valbuena LópezESC GUIDELINES ON DIABETES • Cambio de paradigma en el uso de fármacos hipoglucemiantes  peso de la nueva evidencia científica • Nueva clasificación del riesgo CV • Intervención sobre el estilo de vida y aproximación multifactorial sobre el riesgo cardiovascular • Nuevos objetivos de TA y LDL • Modificaciones en las recomendaciones en terapia antitrombótica CONCLUSIONES

×